-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Iu1sHPBYB4zrvMl/S2IKm1KFW2u3TP3Bt9lPumOmjGU8990m8qC/8sUosnuZiKz+ 6a1DBxhloxPaYf2nNbhdOg== 0001004878-07-000117.txt : 20070920 0001004878-07-000117.hdr.sgml : 20070920 20070801123742 ACCESSION NUMBER: 0001004878-07-000117 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20070801 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CEL SCI CORP CENTRAL INDEX KEY: 0000725363 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 840916344 STATE OF INCORPORATION: CO FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 8229 BOONE BLVD . STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 BUSINESS PHONE: 7035069460 MAIL ADDRESS: STREET 1: 8229 BOONE BLVD. STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 FORMER COMPANY: FORMER CONFORMED NAME: INTERLEUKIN 2 INC DATE OF NAME CHANGE: 19880317 CORRESP 1 filename1.txt CEL-SCI CORPORATION 8229 Boone Blvd. #802 Vienna, VA 22182 (703) 506-9460 August 1, 2007 John Krug Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: CEL-SCI Corporation Form S-3 File No. 333-144522 CEL-SCI Corporation (the "Company") requests that the effective date of the above captioned Registration Statement be accelerated to Friday, August 3, 2007, 11:00 a.m. Eastern time, or as soon as practicable thereafter. The Company understands that: o should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; o the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and o the Company may not assert this action as defense in any proceedings initiated by the Commission or any person under the federal securities laws of the United States. Very Truly Yours, /s/ Patricia Prichep ------------------------------- Patricia Prichep, Senior Vice President of Operations -----END PRIVACY-ENHANCED MESSAGE-----